Health Care [ 10/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom.
Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial.
The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 11, 24 | -0.18 Increased by +63.27% | -0.54 Increased by +66.67% |
| Aug 14, 24 | -0.72 Decreased by -63.64% | -1.43 Increased by +49.65% |
| May 14, 24 | -2.27 Decreased by -382.98% | -4.74 Increased by +52.11% |
| Mar 19, 24 | -6.23 Decreased by -938.33% | -5.89 Decreased by -5.77% |
| Nov 13, 23 | -0.49 Decreased by -16.67% | -0.36 Decreased by -36.11% |
| Aug 9, 23 | -0.44 Increased by +4.35% | -0.50 Increased by +12.00% |
| May 11, 23 | -0.47 Decreased by -11.90% | -0.66 Increased by +28.79% |
| Mar 6, 23 | -0.60 Decreased by -11.11% | -0.48 Decreased by -25.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | N/A Decreased by -100.00% | -3.05 M Decreased by -3.60% | - - |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -3.05 M Increased by +42.10% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 10.00 K Decreased by -37.50% | -1.96 K Increased by +99.97% | Decreased by -19.57% Increased by +99.95% |
| Jun 30, 24 | 4.00 K Decreased by -98.93% | -3.26 M Increased by +40.22% | Decreased by -81.42 K% Decreased by -5.47 K% |
| Mar 31, 24 | 29.00 K Increased by +N/A% | -2.95 M Increased by +49.24% | Decreased by -10.16 K% Decreased by N/A% |
| Dec 31, 23 | 31.00 K Increased by +N/A% | -5.27 M Increased by +28.95% | Decreased by -17.00 K% Decreased by N/A% |
| Sep 30, 23 | 16.00 K Increased by +N/A% | -6.10 M Decreased by -19.64% | Decreased by -38.11 K% Decreased by N/A% |
| Jun 30, 23 | 373.00 K Increased by +N/A% | -5.45 M Decreased by -19.08% | Decreased by -1.46 K% Decreased by N/A% |